Royce & Associates LP Boosts Stake in Astrana Health, Inc. (NASDAQ:ASTH)

Royce & Associates LP lifted its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 122.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 255,552 shares of the company’s stock after buying an additional 140,584 shares during the period. Royce & Associates LP’s holdings in Astrana Health were worth $8,058,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. KBC Group NV bought a new position in Astrana Health during the 3rd quarter valued at about $70,000. Quarry LP bought a new position in Astrana Health during the third quarter valued at approximately $77,000. Quest Partners LLC bought a new position in Astrana Health during the third quarter valued at approximately $133,000. Paloma Partners Management Co bought a new stake in Astrana Health in the 3rd quarter worth approximately $220,000. Finally, Quantbot Technologies LP bought a new stake in Astrana Health in the 3rd quarter worth approximately $244,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Stock Up 4.7 %

Shares of ASTH stock opened at $32.03 on Wednesday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 1.37 and a beta of 1.30. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The company’s fifty day moving average price is $33.97 and its 200-day moving average price is $42.83. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. Sell-side analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ASTH has been the topic of several research analyst reports. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Truist Financial lowered their target price on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday. Stifel Nicolaus dropped their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Bank of America cut their target price on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Robert W. Baird decreased their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.